Redeker I, Albrecht K, Kekow J, et al. - Patients with rheumatoid arthritis under treatment with conventional synthetic (cs), targeted synthetic (ts) or biologic (b) disease-modifying antirheumatic drugs (DMARDs) were compared with respect to the event and incidence rates of herpes zoster (HZ), also known as shingles. Researchers analyzed data of 13,991 patients (62,958 py), with 559 HZ events reported in 533 patients. A 3.6-fold raised risk of HZ was observed in correlation with tsDMARDs and an elevated risk of HZ was recorded under bDMARDs vs csDMARDs.